1. A new era in the treatment of atopic dermatitis. (1st October 2019) Authors: Lebwohl, M. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: 658 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A new era in the treatment of atopic dermatitis. (7th August 2019) Authors: Lebwohl, M. Journal: British journal of dermatology Issue: Volume 181:Number 4(2019) Page Start: 658 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis. Issue Volume 35:Issue S1(2021)Supplement (23rd February 2021) Authors: Lebwohl, M.; Thaçi, D.; Warren, R.B. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Issue S1(2021)Supplement Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. (14th October 2018) Authors: Blauvelt, A.; Reich, K.; Lebwohl, M.; Burge, D.; Arendt, C.; Peterson, L.; Drew, J.; Rolleri, R.; Gottlieb, A.B. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 3(2019) Page Start: 546 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Continued treatment with secukinumab is associated with high retention or regain of response. (17th July 2019) Authors: Augustin, M.; Thaci, D.; Eyerich, K.; Pinter, A.; Radtke, M.; Lauffer, F.; Mrowietz, U.; Gerdes, S.; Pariser, D.; Lebwohl, M.; Sieder, C.; Melzer, N.; Reich, K. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Continued treatment with secukinumab is associated with high retention or regain of response. (1st January 2020) Authors: Augustin, M.; Thaci, D.; Eyerich, K.; Pinter, A.; Radtke, M.; Lauffer, F.; Mrowietz, U.; Gerdes, S.; Pariser, D.; Lebwohl, M.; Sieder, C.; Melzer, N.; Reich, K. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Do we need a patient satisfaction score?. (1st March 2014) Authors: Lebwohl, M. Journal: British journal of dermatology Issue: Volume 170:Number 3(2014:Mar.) Page Start: 494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Do we need a patient satisfaction score?. (March 2014) Authors: Lebwohl, M. Journal: British journal of dermatology Issue: Volume 170:Number 3(2014:Mar.) Page Start: 494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Dupilumab as a treatment for generalized idiopathic pruritus: a report of two cases. (12th February 2020) Authors: Stanger, R.; Rivera‐Oyola, R.; Lebwohl, M. Journal: British journal of dermatology Issue: Volume 182:Number 6(2020) Page Start: 1494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Dupilumab as a treatment for generalized idiopathic pruritus: a report of two cases. (1st June 2020) Authors: Stanger, R.; Rivera‐Oyola, R.; Lebwohl, M. Journal: British journal of dermatology Issue: Volume 182:Number 6(2020) Page Start: 1494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗